Sponsors (2)
The bill strengthens PFAS clinical and public-health guidance and requires community-informed, regularly updated scientific assessments—improving diagnosis and response for affected populations—while creating administrative costs, potential implementation burdens for health systems, and a risk of delays before communities receive guidance.
State and local public-health authorities, clinicians, and PFAS-exposed communities (including low-income and rural communities) will receive evidence-based clinical guidance on PFAS within 5 years, with mandated community engagement and required updates at least every 5 years, improving diagnosis, patient management, and the relevance of public-health responses.
Patients (including those with chronic conditions) and health systems will benefit from a rigorous scientific assessment (to be completed within 2 years) identifying which PFAS are measurable in human tissues, providing a stronger evidence base for clinical and public-health actions.
PFAS-exposed communities and state/local public-health authorities could face delays in receiving guidance if the contracted assessment is delayed or if the National Academies decline participation and alternate arrangements take time.
Hospitals, health systems, and clinicians may incur additional costs and operational burdens to implement new PFAS testing, follow-up protocols, or other recommendations emerging from the guidance.
The requirement to contract for assessments and to maintain and update guidance creates additional administrative work and likely federal spending for ATSDR and its partners.
Based on analysis of 2 sections of legislative text.
Requires ATSDR to contract for an assessment of PFAS measurable in human tissues and to produce clinical recommendations, then publish and update guidance for health authorities and clinicians.
Introduced January 8, 2026 by Maxine Dexter · Last progress January 8, 2026
Requires the Agency for Toxic Substances and Disease Registry (ATSDR) to contract with the National Academies (or a comparable entity) to assess measurable PFAS chemicals in human tissues and produce clinical recommendations. The contractor must finish the initial assessment and recommendations within 2 years; ATSDR must issue and post clinical guidance for state and local public health authorities and health care professionals within 5 years and update both the scientific assessment and the guidance at least every 5 years (or more often if needed). The Director must enter the agreement within 60 days of enactment.